Demographics and baseline characteristics
| Characteristics . | All patients (N = 36) . |
|---|---|
| Age, median (range), y | 68 (26-86) |
| Sex, n (%) | |
| Male | 23 (64) |
| Female | 13 (36) |
| Race/ethnicity, n (%) | |
| White | 30 (83) |
| African American | 4 (11) |
| Asian | 1 (3) |
| Hispanic | 1 (3) |
| Evaluable aspirates for TP53 mutation status, n (%) | 16 (44) |
| Negative | 13 (36) |
| Positive | 3 (8) |
| Evaluable aspirates for FLT3 mutation status, n (%) | 23 (64) |
| Negative | 20 (56) |
| FLT3 ITD | 1 (3) |
| FLT3 TKD mutation | 1 (3) |
| FLT3 ITD and TKD mutation | 1 (3) |
| ECOG performance status, n (%) | |
| 0 | 10 (28) |
| 1 | 21 (58) |
| 2 | 5 (14) |
| Prior stem cell transplant, n (%) | 4 (11) |
| Prior lines of therapy, n (%) | 35 (97) |
| 1 | 10 (28) |
| 2 | 10 (28) |
| ≥3 | 15 (42) |
| Prior treatment with hypomethylating agents, n (%) | |
| Azacitidine | 15 (42) |
| Decitabine | 13 (36) |
| Prior treatment with 7+3, n (%) | |
| Cytarabine plus daunorubicin | 9 (25) |
| Cytarabine plus idarubicin | 7 (19) |
| Cytarabine plus epirubicin | 1 (3) |
| Not specified | 1 (3) |
| Characteristics . | All patients (N = 36) . |
|---|---|
| Age, median (range), y | 68 (26-86) |
| Sex, n (%) | |
| Male | 23 (64) |
| Female | 13 (36) |
| Race/ethnicity, n (%) | |
| White | 30 (83) |
| African American | 4 (11) |
| Asian | 1 (3) |
| Hispanic | 1 (3) |
| Evaluable aspirates for TP53 mutation status, n (%) | 16 (44) |
| Negative | 13 (36) |
| Positive | 3 (8) |
| Evaluable aspirates for FLT3 mutation status, n (%) | 23 (64) |
| Negative | 20 (56) |
| FLT3 ITD | 1 (3) |
| FLT3 TKD mutation | 1 (3) |
| FLT3 ITD and TKD mutation | 1 (3) |
| ECOG performance status, n (%) | |
| 0 | 10 (28) |
| 1 | 21 (58) |
| 2 | 5 (14) |
| Prior stem cell transplant, n (%) | 4 (11) |
| Prior lines of therapy, n (%) | 35 (97) |
| 1 | 10 (28) |
| 2 | 10 (28) |
| ≥3 | 15 (42) |
| Prior treatment with hypomethylating agents, n (%) | |
| Azacitidine | 15 (42) |
| Decitabine | 13 (36) |
| Prior treatment with 7+3, n (%) | |
| Cytarabine plus daunorubicin | 9 (25) |
| Cytarabine plus idarubicin | 7 (19) |
| Cytarabine plus epirubicin | 1 (3) |
| Not specified | 1 (3) |
ECOG, Eastern Cooperative Oncology Group; ITD, internal tandem duplication; TKD, tyrosine kinase domain.